the cancer collaborative

come on in

bridging science, policy and advocacy

how we’re different  the cancer collaborative is a hub for the cancer community. created to foster an environment of collaboration amongst science, policy and advocacy in order to make a meaningful contribution to cancer care.  our goal is to co-create and collaborate with stakeholders to proactively identify the challenges and opportunities, prioritize them and work together to make action-oriented changes on how cancer care is delivered in canada and beyond. better outcomes for cancer patients in canada can only be achieved when we let go of old ideologies- embracing innovation, encouraging collaboration, creating collective purpose and fundamentally changing. bold ideas and fuelling dialogues that adapt and adopt to shifting paradigms.

we can be the catalyst for change



car-t cell therapy


accelerating adoption through collaboration

car-t cell therapy has entered clinical practice.  such a paradigm-shifting and novel cancer therapy that relies on viral production, genetic- modification, cell expansion, quality control/quality analysis, as well as clinical application and toxicity management poses significant challenges to regulatory and reimbursement approval.  .

continuing the conversation to overcome roadblocks to expand access

biosimilar medicines represent a rapidly emerging field that can offer improved accessibility to medicines for patients at reduced expenditure for healthcare systems that are tackling issues of sustainability. the next two years will be important for biosimilars uptake and impact.  biosimilars uptake in oncology can positively impact the financial burden of healthcare systems with the cost savings being reallocated to improve overall health system outcomes, globally.



europe has lead the way in the uptake of biosimilars in the oncology landscape, what learnings and best practices can we learn from their experience as we begin to introduce biosimilars into the canadian context. a discussion that will focus on the practical application of biosimilars in oncology from the european perspective, what worked, what learnings were had and what could this look like in canada. .


our BLOG

car-t. hype or hope

a few weeks ago, I attended the canadian agency for drugs and technologies in health[CADTH]symposium in edmonton, AB. the opening plenary discussion with the was on the hope and hype in healthcare. your perspective on this, of course, depends on how you’re looking at...



colab.notebook ASCO edition

CHICAGO- once again the american society for clinical oncology [ASCO] featured the latest news, information and data about advances in clinical cancer, however the program context also reflected a desire to broaden the reach of those advances and ensure the maximum...



car-t was heralded in 2018 by ASCO as advance of the yr but one that comes with a sticker price shock. decision makers grapple with measuring cost & effectiveness of therapies & value with the sustainability constraints—so is it just hype or hope? blogpost

MUSTREAD health devouring +40% of spending everywhere- ppl still can’t get doctors, a bunch of expensive new obligations is exactly what it needs. But don’t throw money at it. Hope it falls from the sky or something. via @nationalpost

Load More...